Perfil
Samuel Henderson is currently the Chief Scientific Officer at Cerecin, Inc. Previously, he worked as a Principal at The University of Colorado and as a Lead Scientist at Genoplex, Inc. He completed his undergraduate degree at the University of Washington and obtained his doctorate from the University of Chicago.
Cargos activos de Samuel Henderson
| Empresas | Cargo | Inicio |
|---|---|---|
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat central nervous system disorders | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Samuel Henderson.
| Empresas | Cargo | Fin |
|---|---|---|
Genoplex, Inc.
Genoplex, Inc. Packaged SoftwareTechnology Services Develops AI-powered technology platform to simplify the logistics of patient referrals for advanced therapies | Director Técnico/Científico/I+D | - |
The University of Colorado
The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Formación de Samuel Henderson.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 5 |
|---|---|
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat central nervous system disorders | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Colorado
The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genoplex, Inc.
Genoplex, Inc. Packaged SoftwareTechnology Services Develops AI-powered technology platform to simplify the logistics of patient referrals for advanced therapies | Technology Services |
- Bolsa de valores
- Insiders
- Samuel Henderson
















